Selumetinib - AstraZeneca

Drug Profile

Selumetinib - AstraZeneca

Alternative Names: AR 00142886; AR 142886 X; ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; MK 5618; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Cincinnati Children's Hospital Medical Center; Merck & Co; National Cancer Centre (Singapore); National Cancer Institute (USA); Netherlands Cancer Institute; Samsung Medical Center; University Health Network; University of Cambridge; University of Liverpool
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Neurofibromatoses; Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioma; Histiocytosis; Neurofibromatoses; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Phase I/II Astrocytoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Liver cancer; Malignant melanoma; Multiple myeloma; Thyroid cancer

Most Recent Events

  • 27 Sep 2018 Discontinued - Phase-II for Thyroid cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom (PO)(AstraZeneca Pipeline, September 2018)
  • 05 Sep 2018 Phase-I clinical trials in Neurofibromatosis (In volunteers) in USA (PO, Capsule, Granules) (NCT03649165 )
  • 28 Aug 2018 AstraZeneca plans a phase I bioavailability and food effect trial in Healthy volunteers (Combination therapy) in USA in September 2018 (NCT03649165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top